Heron Therapeutics (HRTX) Q4 2025 earnings review
Acute Care Surges, But Oncology Collapse Drags Total Revenue
Heron's Q4 tells a tale of two diverging franchises. The Acute Care segment (ZYNRELEF and APONVIE) is accelerating rapidly, up 57% YoY. However, the legacy Oncology cash cow reversed hard, plummeting 20% and dragging total company revenue to a 0.5% YoY decline. Profitability also reversed, with Q4 net income flipping back to a $3.0M loss after celebrating profitability a year ago. Despite the bottom-line and total revenue misses, management is guiding for an accelerating FY26 top line as the product mix permanently shifts toward the high-growth Acute Care portfolio.
🐂 Bull Case
ZYNRELEF and APONVIE are delivering on their promises, growing 48% and 97% YoY respectively in Q4. Permanent CMS J-Codes and completed VAN transitions remove major friction points for adoption.
APONVIE's inclusion in the new Fifth Consensus Guidelines for PONV and ZYNRELEF's permanent J-Code (J0668) provide structural advantages for FY26 acceleration.
🐻 Bear Case
CINVANTI revenues dropped 14.7% YoY in Q4. The competitive pressure management warned about in earlier quarters has materialized, neutralizing Acute Care's gains.
After achieving a $3.7M net income in Q4 2024, the company reversed to a $3.0M net loss in Q4 2025. Generating sustained GAAP profitability remains elusive.
⚖️ Verdict: ⚪
Neutral. The underlying thesis—transitioning from Oncology to Acute Care—is working on a product level. However, the steep decline in CINVANTI offset all top-line gains this quarter, and the reversal to a net loss contradicts the 'exceptional momentum' narrative.
Key Themes
Acute Care Portfolio Accelerating
The Acute Care franchise generated $16.3M in Q4, an accelerating 57.3% YoY growth rate. ZYNRELEF contributed $12.5M (+48.2% YoY) and APONVIE added $3.8M (+97.4% YoY). This segment is successfully executing its turnaround, heavily supported by the newly established dedicated sales teams and the CrossLink partnership.
Oncology Franchise Collapse
Management's 'conservative outlook' on the Oncology franchise from earlier this year was justified. Q4 Oncology revenue reversed sharply, falling 20.2% YoY to $24.2M. CINVANTI, the company's historical cash cow, declined 14.7% YoY to $22.9M, indicating severe competitive and pricing pressures. SUSTOL is effectively dead, dropping 62.3% YoY to $1.3M as commercialization winds down.
Regulatory and CMS Policy Tailwinds
Macro-level reimbursement friction has been a historical barrier, but this is reversing. CMS granted permanent, product-specific J-Codes for both ZYNRELEF (J0668, effective Oct 1) and APONVIE (J8502). Additionally, APONVIE was officially included in the Fifth Consensus Guidelines for the Management of PONV, offering a critical validation tool for the new dedicated sales team.
Profitability Trajectory Reversing
A major concern contradicting the positive management narrative is the return to negative earnings. Despite celebrating a 'financial turnaround' in Q4 2024 with a $3.7M net income, Q4 2025 reversed to a $2.95M net loss. While full-year Adjusted EBITDA improved to $14.7M, the GAAP bottom-line regression highlights the cost of funding the Acute Care pivot.
Product Innovation: Prefilled Syringe & VAN
The operational hurdle of drug preparation in the OR is being systematically dismantled. The transition to the ZYNRELEF Vial Access Needle (VAN) is completely finished, optimizing handling. Looking ahead, the development of the true end-game innovation—a ready-to-use Prefilled Syringe—is progressing, with FDA approval anticipated in mid-to-late 2027.
Approaching Debt Maturity Wall
Heron ended Q4 with $46.6M in cash and short-term investments, down from $50.7M in Q1 2025. With a significant non-current convertible note balance ($32.7M net on the balance sheet, but historically related to a much larger Baker Brothers note maturing in May 2026), the company's liquidity runway relative to its debt obligations requires close monitoring as the deadline approaches.
Other KPIs
Accelerating. Up significantly from $6.4 million in FY24. This marks a solid achievement for the full year and beats the upper end of the company's previously raised $9-$13 million guidance range, proving that despite Q4's GAAP net loss, underlying cash operating metrics are improving.
Stable. Total operating expenses were down slightly from $117.2 million in FY24. SG&A increased modestly (Sales & Marketing up to $49.1M from $47.1M), reflecting investments in dedicated sales forces, which was offset by Research & Development dropping to $12.4M from $16.7M.
Guidance
Accelerating. The midpoint of $178 million implies ~15% YoY growth over FY25's $154.9 million. This suggests management is highly confident that the surging Acute Care segment will comfortably outpace any further declines in the CINVANTI oncology business.
Stable. The midpoint of $15 million is essentially flat compared to FY25's actual print of $14.7 million. This implies that the incremental gross profit from the $23M in projected new revenue will be reinvested back into the business (likely sales expansion) rather than dropping to the bottom line.
Key Questions
Oncology Margin vs Volume Mix
CINVANTI declined nearly 15% in Q4. Is this driven entirely by price/ASP concessions to maintain formulary access against competitors, or are we losing unit volume? How does this impact gross margins going into 2026?
Debt Maturity Strategy
With cash and short-term investments at $46.6 million and Adjusted EBITDA guided flat around $15 million, what are the explicit plans to address the upcoming convertible debt maturity in May 2026?
Path to Sustainable GAAP Net Income
Despite beating Adjusted EBITDA targets for FY25, Q4 reversed back to a GAAP net loss. What is the revenue run-rate required for the Acute Care franchise to generate consistent, unadjusted GAAP profitability?